Earnings History Data for SpringWorks Therapeutics, Inc. (SWTX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-11-2024	PM		SWTX	SpringWorks Therapeutics, Inc.	2,520	-0.72	-0.76	-1.27	SpringWorks Therapeutics gives mixed Q3 results [11/12/2024 6:33 AM]	32.91	-0.61 (-1.82%)	29.44	-4.08 (-12.17%)	18.00 - 53.92	3,870,689	920,000	530,175
SpringWorks Therapeutics gives mixed Q3 results [11/12/2024 6:33 AM] SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [2024-11-12 06:30AM] Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q3 2024 Result [Nov-11-24 07:08AM] SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting [Nov-11-24 07:00AM] SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology [Nov-11-24 06:30AM]
07-08-2024	PM		SWTX	SpringWorks Therapeutics, Inc.	2,480	-0.54	-1.12	-1.25	SpringWorks Therapeutics GAAP EPS of -$0.54 beats by $0.58, revenue of $59.73M beats by $25.15M [8/7/2024 6:33 AM]	33.98	0.76 (2.29%)	38.25	5.03 (15.14%)	18.00 - 53.92	2,272,049	930,000	4,698
SpringWorks Therapeutics Q2 2024 Earnings Preview [8/6/2024 11:21 AM] SpringWorks Therapeutics GAAP EPS of -$0.54 beats by $0.58, revenue of $59.73M beats by $25.15M [8/7/2024 6:33 AM]
02-05-2024	PM		SWTX	SpringWorks Therapeutics, Inc.	3,430	-1.18	-1.17	-1.18	SpringWorks Therapeutics GAAP EPS of -$1.18, revenue of $21M [5/2/2024 6:36 AM]	43.44	-3.41 (-7.27%)	47.50	0.66 (1.41%)	18.00 - 53.92	3,253,116	950,000	42,962

02-08-2023	PM		SWTX	SpringWorks Therapeutics	1,962	-1.25	-1.25	0.00	SpringWorks Therapeutics GAAP EPS of -$1.25 [8/2/2023 12:25 PM]	27.88	-1.97 (-6.60%)	0.0	0.0 (0.00%)	21.04 - 39.78	487,097	400,000	0
SpringWorks Therapeutics GAAP EPS of -$1.25 [8/2/2023 12:25 PM]
03-05-2023	PM		SWTX	SpringWorks Therapeutics	1,501	-1.18	-1.25	0.00	SpringWorks Therapeutics GAAP EPS of -$1.18 beats by $0.07 [5/3/2023 10:27 AM]	24.04	0.71 (3.07%)	0.0	0.0 (0.00%)	13.60 - 51.03	885,599	570,000	0
SpringWorks Therapeutics GAAP EPS of -$1.18 beats by $0.07 [5/3/2023 10:27 AM]
28-02-2023	PM		SWTX	SpringWorks Therapeutics	1,858	-1.19	-1.21	0.00	SpringWorks Therapeutics GAAP EPS of -$5.21 beats by $0.04 [2/28/2023 7:44 AM]	31.89	1.40 (4.59%)	0.0	0.0 (0.00%)	13.60 - 65.92	694,113	570,000	0
SpringWorks wins FDA priority review for lead candidate [2/27/2023 7:33 AM] SpringWorks Therapeutics GAAP EPS of -$5.21 beats by $0.04 [2/28/2023 7:44 AM]
04-08-2022	PM		SWTX	SpringWorks Therapeutics, Inc.	1,400	-1.41	-1.26	-0.97	SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15 [8/4/2022 8:40 AM]	34.45	3.41 (10.97%)	31.04	0.0 (0.00%)	13.60 - 88.62	510,390	580,000	14,444
SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15 [8/4/2022 8:40 AM] SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights [Aug-04-22 06:30AM]
04-11-2021	PM		SWTX	SpringWorks Therapeutics	3,400	-0.84	-0.77	0.00	SpringWorks Therapeutics EPS misses by $0.08 [11/4/2021 6:43 AM]	72.59	1.64 (2.31%)	72.59	0.0 (0.00%)	51.57 - 96.48	223,130	320,000	4,093
SpringWorks Therapeutics EPS misses by $0.08 [11/4/2021 6:43 AM] SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights [Nov-04-21 06:30AM]
04-08-2021	PM	6:30 AM ET (Aug 4)	SWTX	Springworks Therapeutics Inc.	4,185	-0.97	-0.70	0.00	SpringWorks Therapeutics EPS misses by $0.30 [8/4/2021 6:37 AM]	86.05	0.43 (0.50%)	86.05	0.0 (0.00%)	36.71 - 96.48	109,107	200,000	5,699
SpringWorks Therapeutics EPS misses by $0.30 [8/4/2021 6:37 AM] SpringWorks Therapeutics to initiate early-stage mirdametinib cancer study [8/3/2021 6:59 AM] SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights [Aug-04-21 06:30AM] SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference [Aug-03-21 09:00AM] SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations [Aug-03-21 06:30AM]
06-05-2021	PM		SWTX	Springworks Therapeutics Inc.	3,384	-0.62	-0.51	0.00	SpringWorks Therapeutics EPS misses by $0.11 [5/6/2021 6:43 AM]	71.16	2.72 (3.97%)	71.16	0.0 (0.00%)	29.41 - 96.48	342,162	220,000	2,474
SpringWorks Therapeutics EPS misses by $0.11 [5/6/2021 6:43 AM] SpringWorks Therapeutics in-licenses rights to TEAD inhibitor portfolio in solid tumors [5/6/2021 6:30 AM] SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights [May-06-21 06:30AM] SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio [May-06-21 06:04AM]